PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.
Natalie B CollinsRose Al AbosyBrian C MillerKevin BiQihong ZhaoMichael QuigleyJeffrey J IshizukaKathleen B YatesHans W PopeRobert T MangusoYashaswi ShresthaMarc WadsworthTravis HughesAlex K ShalekJesse S BoehmWilliam C HahnJohn G DoenchW Nicholas HainingPublished in: Journal for immunotherapy of cancer (2022)
PI3K activation enables tumor immune evasion by promoting an inhibitory myeloid microenvironment. Activating mutations in PI3K may be useful as a biomarker of poor response to immunotherapy. Our data suggest that some oncogenes promote tumorigenesis by enabling tumor cells to avoid clearance by the immune system. Identification of those mechanisms can advance rational combination strategies to increase the efficacy of immunotherapy.